Study to assess safety and effectiveness of a minimally invasive, zero-capital, outpatient device therapy for BPH MILWAUKEE, April 23, 2025 /PRNewswire/ -- Rivermark Medical, a urology-focused medical ...
Wisconsin-based medtech Rivermark Medical has secured $20m in a Series D financing round – supporting the company's late-stage clinical activities being used for approval of its flagship device for ...
MILWAUKEE, Oct. 10, 2024 /PRNewswire/ -- Rivermark Medical, a leader in minimally invasive solutions for Benign Prostatic Hyperplasia (BPH), today announced the close of a $30 million Series C ...
RIVERMARK MEDICAL ANNOUNCES SUCCESSFUL FIRST-IN-HUMAN USE OF ITS FLOSTENT SYSTEM FOR SYMPTOMATIC BPH
MILWAUKEE, Jan. 10, 2023 /PRNewswire/ -- Rivermark Medical TM, a company dedicated to developing first-line device therapy for benign prostatic hyperplasia (BPH), announced today the successful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results